Carcemia

PreclinicalSmall molecule

HHikma Pharmaceuticals LLC

Carcemia is one of 25 small molecule programs targeting Myeloid Leukemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myeloid LeukemiaActive, not recruiting

Myeloid LeukemiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

29 competitors in Myeloid Leukemia

#DrugCompanyPhaseTrials

Gleevec

Novartis

Approved

38 2

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

35 3

Tasigna

AAzurity Pharmaceuticals

Approved

25 4

Bosulif

PPrism Pharmaceuticals

Approved

11 5

Venclexta

AbbVie

Approved

1 6

Dacogen

Sun Pharmaceutical Industries, Inc.

Lynparza

Novantrone

1 9

Cerubidine

HHikma Pharmaceuticals LLC

Scemblix

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Recruiting

Myeloid Leukemia

NCT05282108

Clinical

Trials by Indication[1]

Myeloid Leukemia1 trial

Efficacy and Safety of Generic Imatinib (Carcemia®) Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia

Recruiting·HHikma Pharmaceuticals LLC··NCT05282108·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Carcemia. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Carcemia compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Carcemia. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hikma Pharmaceuticals LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHikma Pharmaceuticals LLC

Carcemia

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News